Diagnostic Value of Seven Autoantibodies Combined with CEA and CA199 in Non-Small Cell Lung Cancer.

BACKGROUND: This study aimed to analyze the diagnostic value of seven autoantibodies (7-AABs) combined with carcinoembryonic antigen (CEA) and carbohydrate antigen-199 (CA199) in non-small cell lung cancer (NSCLC) and provide a new method for early screening of NSCLC. METHODS: The serum levels of 7-AABs, CEA, and CA199 were determined in the NSCLC group (n = 615), benign lung disease group (n = 183), healthy control group (n = 236), and the other tumor group (n = 226). The receiver operating characteristic area under the curve (AUC) analyses were conducted to evaluate the diagnostic efficiency of 7-AABs combined with CEA and CA199 in NSCLC. RESULTS: The positive rate of 7-AABs detection was higher than that of a single antibody detection. The positive rate of the combination of 7-AABs in NSCLC group (27.8%) was significantly higher than that of the benign lung disease group (15.8%) and healthy control group (11.4%). The positive rate of MAGE A1 was higher in patients with squamous cell carcinoma than adenocarcinoma. The levels of CEA and CA199 in the NSCLC group were significantly higher than those of the healthy control group, but had no statistical differences compared with those of benign lung disease group. The sensitivity, specificity, and AUC of the 7-AABs were 27.8%, 86.6%, and 0.665, respectively. The combination of 7-AABs with CEA and CA199 increased the sensitivity to 34.8% and AUC to 0.689. CONCLUSIONS: The diagnostic efficiency was enhanced by a combination of 7-AABs, CEA, and CA199 in NSCLC, which was helpful in the screening of NSCLC.

Efficacy of autoantibodies combined with tumor markers in the detection of lung cancer.

BACKGROUND: The purpose of this study was to explore the detection value of seven autoantibodies (TAAbs): p53, PGP9.5, SOX2, GBU4-5, MAGE A1, CAGE, and GAGE7 and three tumor markers: CYFRA21-1, NSE, and SCCA in the diagnosis of lung cancer. METHODS: ELISA was used to detect the levels of the TAAbs, and chemiluminescence immunoassay was used to test the levels of the tumor markers. The diagnostic efficacy of the TAAbs combined with the tumor markers for lung cancer was evaluated by receiver operating characteristic (ROC) curves. RESULTS: The positive rate of the combined detection of seven TAAbs and three tumor markers in lung cancer (37.8%) was higher than that in other three groups. The positive rates of SOX2, GAGE7, MAGE A1, CAGE, CYFRA21-1, and SCCA had differences among the four groups. Compared with the benign lung disease group, only GAGE7, CYFRA21-1, and SCCA differed among the groups. The combined sensitivity of the TAAbs was 29.07% (AUC, 0.594), the combined sensitivity of all the markers was 37.76% (AUC, 0.660 [p < 0.05]), and Youden's index was 0.196. In the lung cancer group, CYFRA21-1 had a significant difference in age and sex, and SOX2, MAGE A1, CYFRA21-1, NSE, and SCCA were significantly different in pathological type and TNM. In contrast, p53 and GBU4-5 showed no significant differences in age, sex, pathological type, and TNM. CONCLUSIONS: The combined detection of seven TAAbs and three tumor markers could be useful in early diagnosis of lung cancer.

CircRNA6783 Inhibits Cell Proliferation and Promotes Apoptosis in Lung Adenocarcinoma.

Purpose: Circular RNA (circRNA) serves an important role in tumour genesis and development. But, little is known about its role in lung adenocarcinoma (LA). This study aimed to investigate circRNA6783 expression in peripheral whole blood (PWB) of LA and controls and explore its effect on proliferation and apoptosis in human lung adenocarcinoma cells (LAC). Patients and Methods: The levels of circRNA6783 in LA cell lines and peripheral whole blood (PWB) of 40 patients and 30 controls were detected by real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR). In order to explore the effect of circRNA6783 on LA behavior, we overexpressed circRNA6783 in NCI-H1975 cells. The impact on the proliferation of tumor cells was then examined by Cell Counting Kit 8 (CCK8) assay, and the effects on apoptosis in the cell line were detected using flow cytometry. Results: The expression levels of circRNA6783 were significantly higher in LA cell lines and PWB (P < 0.05). The diagnostic value of the area under the receiver operating characteristic curve (AUC) was 0.830, with a sensitivity of 60% and specificity of 96.7%. In addition, functional experiments showed that overexpression of circRNA6783 restrained cell proliferation, significantly increased spontaneous apoptosis. Conclusion: CircRNA6783 was upregulated in LA PWB. In vitro assessment demonstrated that circRNA6783 could act as a potential biomarker for LA diagnosis.

Development and Validation of a UPLC-MS/MS Method for the Quantitative Determination and Pharmacokinetic Analysis of Cirsimarin in Rat Plasma.

Cirsimarin is a bioactive antilipogenic flavonoid isolated from the cotyledons of Abrus precatorius and represents one of the most abundant flavonoids present in this plant species. Cirsimarin exhibits excellent antioxidant, lipolysis, and other biological properties; it can effectively trigger lipid movement and demonstrates antiobesity effects. In this work, an ultra-high-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method was developed for the determination of cirsimarin in rat plasma after intravenous administration. A standard curve of cirsimarin in blank rat plasma was generated over the concentration range of 1-3000 ng/mL. Six rats were administered cirsimarin intravenously (1 mg/kg). The method only required 50 µL of plasma for sample preparation, and the plasma proteins were precipitated with acetonitrile to pretreat the plasma sample. The precisions of cirsimarin in rat plasma were less than 14%, while the accuracies varied between 92.5% and 107.3%. In addition, the matrix effect varied between 103.6% and 107.4%, while the recoveries were greater than 84.2%. This UPLC-MS/MS method was then applied in measuring the pharmacokinetics of cirsimarin in rats. The AUC(0-t) values of cirsimarin from the pharmacokinetic analysis were 1068.2 ± 359.2 ng/mL·h for intravenous administration. The half-life (t 1/2) was 1.1 ± 0.4 h (intravenous), indicating that the metabolism of the compound was quick in the rats. Exploring the pharmacokinetics of cirsimarin in vivo can help better understand its metabolism.

Association of ERCC1 and ERCC2 Gene Polymorphisms with Pancreatic Cancer Risk: A Meta-Analysis.

In this meta-analysis, all relative literature was retrieved through the Embase and PubMed databases. Moreover, the Stata 12.0 software package was applied to calculate the pooled odds ratio (OR) of the 95% confidence interval (CI). A total of seven studies was identified to analyze the relation between ERCC1 and ERCC2 gene polymorphisms and pancreatic cancer risk. The results showed that ERCC2 rs13181 polymorphism was associated with pancreatic cancer (CC vs. AA: OR = 1.53, 95% CI = 1.24-1.90; AC vs. AA: OR = 1.06, 95% CI = 0.92-1.22; dominant model: OR = 1.16, 95% CI = 1.02-1.32; recessive model: OR = 1.39, 95% CI = 0.13-1.70). For ERCC1 rs3212986 polymorphism, a significant correlation with pancreatic cancer risk was found (TT vs. GG: OR = 2.33, 95% CI = 1.73-3.14; GT vs. GG: OR = 1.34, 95% CI = 1.11-1.63; dominant model: OR = 1.50, 95% CI = 1.25-1.80; recessive model: OR = 1.98, 95% CI = 1.50-2.62). A lack of association was found for ERCC1 rs11615 polymorphism (TT vs. CC: OR = 1.21, 95% CI = 0.93-1.56; CT vs. CC: OR = 1.02, 95% CI = 0.87-1.21; dominant model: OR = 1.43, 95% CI = 0.80-2.50; recessive model: OR = 0.99, 95% CI = 0.65-1.51).

Clinical value of seven autoantibodies combined detection in the diagnosis of lung cancer.

BACKGROUND: To analyze the clinical value of seven autoantibodies (p53, PGP9.5, SOX2, GAGE7, GBU4-5, MAGE A1 and CAGE) in lung cancer patients. METHODS: ELISA was used to determine serum levels of seven autoantibodies in 177 patients with lung cancer, 201 healthy persons, and 210 patients with benign pulmonary diseases. Positive rates of 7 autoantibodies were analyzed; receiver operating characteristic (ROC) curves were drawn to analyze their diagnostic efficiency in lung cancer and to compare the positive rate of seven kinds of autoantibody combined detection of lung cancer patients with different clinicopathological features. RESULTS: The positive rate of seven autoantibodies in all subjects was 13.44%. The positive rate of seven autoantibodies in lung cancer was 25.42%. The positive rate of the combined detection of seven autoantibodies in the lung cancer group was significantly higher than that in healthy control group (χ2  = 19.76, P < .001) and benign lung disease group (χ2  = 21.44, P < .001). Sensitivity, specificity, and AUCROC of the seven autoantibodies were 25.42%, 91.75%, and 0.683, respectively. Sensitivity and AUCROC were higher than those of the single autoantibody detection. Positive rates of seven autoantibodies in different pathological types and clinical stages of lung cancer patients were significantly different (P < .05). CONCLUSIONS: The combined detection of 7 autoantibodies in lung cancer has some clinical value for the auxiliary diagnosis of lung cancer.

Influenza A-associated severe pneumonia in hospitalized patients: Risk factors and NAI treatments.

OBJECTIVE: The risk factors and the impact of NAI treatments in patients with severe influenza A-associated pneumonia remain unclear. METHODS: A multicenter, retrospective, observational study was conducted in Zhejiang, China during a severe influenza epidemic in August 2017-May 2018. Clinical records of patients (>14 y) hospitalized with laboratory-confirmed influenza A virus infection and who developed severe pneumonia were compared to those with mild-to-moderate pneumonia. Risk factors related to pneumonia severity and effects of NAI treatments (monotherapy and combination of peramivir and oseltamivir) were analyzed. RESULTS: 202 patients with influenza A-associated severe pneumonia were enrolled, of whom 84 (41.6%) had died. Male gender (OR = 1.782; 95% CI: 1.089-2.917; P = 0.022), chronic pulmonary disease (OR = 2.581; 95% CI: 1.447-4.603; P = 0.001) and diabetes mellitus (OR = 2.042; 95% CI: 1.135-3.673; P = 0.017) were risk factors related to influenza A pneumonia severity. In cox proportional hazards model, severe pneumonia patients treated with double dose oseltamivir (300mg/d) had a better survival rate compared to those receiving a single dose (150 mg/d) (HR = 0.475; 95%CI: 0.254-0.887; P = 0.019). However, different doses of peramivir (300 mg/d vs. 600 mg/d) and combination therapy (oseltamivir-peramivir vs. monotherapy) showed no differences in 60-day mortality (P = 0.392 and P = 0.658, respectively). CONCLUSIONS: Patients with male gender, chronic pulmonary disease, or diabetes mellitus were at high risk of developing severe pneumonia after influenza A infection. Double dose oseltamivir might be considered in treating influenza A-associated severe pneumonia.

Circular RNA expression profile in peripheral whole blood of lung adenocarcinoma by high: Throughput sequencing.

BACKGROUND: Lung adenocarcinoma (LA) is a most common form of non-small cell lung cancer (NSCLC). To date, there are still no effective early diagnosis methods for patients to be cured in time. Noncoding RNA plays an important role in oncogenesis and tumor development. The expression profile of circular RNA (circRNA) in peripheral whole blood (PWB) of LA has not been systematically investigated. In this study, we identified the differentially expressed (DE) circRNAs in PWB of LA by high-throughput sequencing. METHODS: Five paired LA and normal participants PWB samples were chosen to investigate the expression profile of circRNAs by high-throughput sequencing. Twenty LA and 10 normal controls PWB samples were subjected to reverse-transcription polymerase chain reaction (RT-PCR) for validation of circRNAs expression profile. Gene Ontology (GO) functional analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and circRNA-miRNA network analysis was also performed to predict the function of circRNAs in PWB. RESULTS: A total of 10566 circRNAs were identified and annotated, most of the circRNAs were exonic (78.14%). Statistical analysis revealed 4390 DE circRNAs, in which were 3009 upregulated circRNAs and1381downregulated circRNAs in LA. RT-PCR results showed that circRNA expression in LA was higher than that in controls. GO functional analysis, KEGG pathway analysis, and circRNA-miRNA network analysis all showed that circRNAs correlated with tumor development and progression to a certain degree. The current study is the first to systematically characterize and annotate circRNA expression in PWB of LA. Some host genes of the DE circRNAs were involved in tumor signaling pathway and had complicated correlations with tumor related miRNAs, indicating that circRNAs might involve in development and progression of LA. CONCLUSIONS: Our study revealed that circRNAs were abnormally expressed in PWB of LA, which might offer potential targets for the early diagnosis of the disease and new genetic insights into LA.

[Research Progress of Circular RNA in Lung Cancer].

Lung cancer is one of the most important malignant tumors of human health and life in the world, and is the leading cause of death in the world. At present, it is believed that it is caused by many factors. Circular RNA (circRNA), as a class of non-coding RNA family, has covalently closed loop structure. CircRNA is abundant in different cells. CircRNAs due to the special structure, with a high degree of specificity, conservation and stability, may have a potential clinical value in the development of lung cancer. The biological function of circRNA is multi-faceted, including miRNA sponge, transcriptional and alternative splicing, protein coding , and so on. Currently, the role and mechanism of circRNA in lung cancer is not very clear. In this paper, the characteristics, function, mechanism and the role of circRNAs in the occurrence and development of lung cancer are reviewed.
.

Comparison between Elecsys HBsAg II and Architect assays for quantification of serum hepatitis B surface antigen in Chinese patients with chronic hepatitis B.

BACKGROUND: Chronic hepatitis B (CHB) is an important global health problem. Recent innovations have rendered quantification of serum hepatitis B surface antigen (HBsAg) a valuable tool in hepatitis B virus (HBV) disease management and for determining the effectiveness of drug treatment. The aim of the present study was to compare the performances of the Elecsys HBsAg II and Abbott Architect HBsAg assays in Chinese patients with CHB, with predominantly genotypes B and C. METHODS: A dilution protocol was developed for the Elecsys assay to allow quantification of HBsAg levels. Sera were obtained from patients with various HBV genotypes, including HBV mutants, and longitudinal samples were obtained from patients undergoing antiviral treatment. RESULTS: There was a significant overall correlation between the Elecsys and Architect assays (r = 0.9881; p < 0.001). There were good correlations between the results of the two assays in terms of HBsAg levels in CHB samples (r = 0.9625-0.9974), in samples with low HBsAg levels (r = 0.9722, p < 0.001), across two genotypes (HBV genotype B, r = 0.9758, p < 0.001; HBV genotype C, r = 0.9943, p < 0.001), in samples with YMDD mutations (r = 0.9625, p < 0.001), and in samples from patients receiving anti-HBV treatment (r = 0.9974, p < 0.001). Bland-Altman analysis showed a discordance between the assays in all tested patients with CHB of 0.09 log IU/mL. CONCLUSIONS: Mean HBsAg levels detected by the Architect assay were higher than those obtained by the Elecsys assay. There was a good correlation between the results of the Elecsys HBsAg II and Abbott Architect HBsAg assays in patients with CHB, especially those with genotype C.

Nucleotide excision repair gene ERCC1 19007T>C polymorphism contributes to lung cancer susceptibility: a meta-analysis.

AIMS: Association studies of ERCC1 19007T>C polymorphism and lung cancer have yielded inconsistent results, possibly because single studies often lack sufficient statistical power. METHODS: We examined the association by performing a meta-analysis. Two investigators independently searched the Google Scholar, PubMed, and CNKI Databases. Summary odds ratios (ORs) and 95% confidence intervals (95% CIs) for 19007T>C polymorphism and lung cancer were calculated in a fixed-effects model and a random-effects model, when appropriate. Publication bias was evaluated using Begg's funnel plot. RESULTS: Overall, the meta-analysis included 7 case-control studies for each polymorphism with 3840 confirmed lung cancer cases and 4712 healthy controls in total. Meta-analysis results showed a significant association between 19007T>C polymorphism and lung cancer risk (CC vs. TT: OR=0.72, 95% CI 0.53-0.99; CT vs. TT: OR=0.84, 95% CI 0.73-0.98; Dominant model: OR=0.70, 95% CI 0.52-0.95). Further stratified analyses conducted by ethnicity reveal a statistically significant association in Asians (Dominant model: OR=0.63, 95% CI 0.43-0.93), but no significant association in Europeans. CONCLUSIONS: This meta-analysis suggests that the ERCC1 19007T>C polymorphism may be associated with lung cancer risk in Asians, while larger scale association studies are necessary to further validate the association of 19007T>C polymorphism with lung cancer risk.

[The clinical significance of hepatitis B virus large surface protein in the diagnosis and treatment of patients with hepatitis B].

OBJECTIVE: To explore the sigificance of HBV-LP in the HBV replication and anti-virus treatment efficacy assessment by detect the serum HBV-LP and HBV DNA and Pre-S1 and HBV serum markers. METHODS: Serum HBV-LP, Pre-S1 and HBV serologic markers were measured by enzyme-linked immunosobent assay(ELISA), fluorescent PCR method to detect serum HBV DNA content in the 220 cases infected serum of CHB. Treated with adefovir dipivoxil antiviral therapy, and mesured the setologic indicators after 12 weeks, 24 weeks,36 weeks and 48 weeks. RESULTS: The detection rate of HBV-LP and HBV DNA detection rate no significant difference in patients with chronic hepatitis B, and significantly higher than the Pre-S1 and HBeAg detection rate. HBV-LP positive rate also similar to the HBV DNA positive rate in HBeAg negative CHB patients. In the anti-virus therapy, the declined of HBV-LP similar to HBV DNA. CONCLUSIONS: HBV-LP can reflect the HBV replication, is a good chronic hepatitis B diagnosis and efficacy evaluation index.

[Value of combined detection of GP73 and alpha-fetoprotein in diagonosis of hepatocellular carcinoma].

OBJECTIVE: To explore the diagnostic value of the measurement of serum Golgi protein 73 (GP73) in the diagnosis of hepatocellular carcinoma (HCC). METHODS: Enzyme-linked immunosorbent assay (ELISA) was used to detect the serum GP73 in the 81 cases of HCC, 71 cases of chronic hepatitis or cirrhosis (CH/LC) and 65 cases of healthy blood donors, and to evaluate the sensitivity and specificity in the diagnosis of HCC through the ROC curves. RESULTS: The average levels of serum GP73 in HCC, CH/LC and Normal groups were (152.67 +/- 33.59) ng/ml, (93.15 +/- 20.02) ng/ml and (58.95 +/- 17.29) ng/ml(o) After calculating through the ROC curves, 120 ng/ml was set as the optimal cut-off point, GP73 has a sensitivity of 77.80% and a specificity of 78.00%. CONCLUSIONS: GP73 as a serum marker in the diagnosis of HCC had a higher sensitivity than AFP, and the combined detection of GP73 and AFP could improve HCC diagnosis.